How should vomiting in a patient taking Eliquis (apixaban) be evaluated and managed?

Management of Vomiting in Patients Taking Eliquis (Apixaban)

If a patient on Eliquis vomits shortly after taking a dose, do not give a replacement dose unless the intact tablet is visible in the vomitus; if a dose is missed entirely, take the next scheduled dose at the regular time without doubling up 1.

Key Dosing Principles

The FDA label for Eliquis provides clear guidance on missed doses that applies to vomiting scenarios:

• If you miss a dose: Take it as soon as you remember
• Critical rule: Do not take more than one dose at the same time to make up for a missed dose 1
• This means if vomiting occurs and you're uncertain whether the drug was absorbed, err on the side of caution and wait for the next scheduled dose

When Vomiting Represents a Bleeding Concern

Vomiting itself may be a sign of gastrointestinal bleeding in anticoagulated patients. You must immediately assess for:

Major Bleeding Criteria (any one of these):

• Hematemesis (vomiting blood)
• Coffee-ground emesis (partially digested blood)
• Hemodynamic instability
• Hemoglobin decrease ≥2 g/dL
• Need for ≥2 units of red blood cells 1

Immediate Actions if Bleeding is Suspected:

For major GI bleeding 2:

1. Stop Eliquis immediately
2. Provide supportive care and volume resuscitation
3. Administer andexanet alfa (specific reversal agent for apixaban):
   • Low dose: 400 mg IV bolus followed by 4 mg/min infusion for 120 minutes
   • High dose: for larger doses taken <8 hours prior or unknown timing
4. If andexanet alfa unavailable, use prothrombin complex concentrate (PCC) or activated PCC
5. Consider activated charcoal if ingestion was within 2-4 hours 2

For non-major bleeding 2:

• Stop Eliquis temporarily
• Provide local therapy and supportive care
• Do NOT administer reversal agents
• Assess for contributing factors (thrombocytopenia, uremia, liver disease)

When Vomiting is NOT Related to Bleeding

If vomiting is due to gastroenteritis, medication side effects, or other non-bleeding causes 3:

• Continue Eliquis if the patient can tolerate oral intake and there's no evidence of bleeding 2
• Address the underlying cause of vomiting
• Ensure adequate hydration to maintain renal function (important for apixaban clearance)
• Monitor for dehydration-induced acute kidney injury, which could increase apixaban levels

Common Pitfalls to Avoid:

1. Don't reflexively give extra doses after vomiting—this increases bleeding risk
2. Don't assume all vomiting is benign—always assess for occult GI bleeding with hemoglobin check if vomiting persists
3. Don't restart anticoagulation too quickly after a major bleed—wait until hemostasis is achieved and the bleeding source is identified 2

Restarting Anticoagulation After Bleeding

Once bleeding is controlled, restart timing depends on 2:

Delay restart if:

• Bleed occurred at a critical site (intracranial, intraspinal, intraocular, pericardial, retroperitoneal)
• High risk of rebleeding
• Source not yet identified
• Surgical procedures planned

Can restart when:

• Hemostasis achieved
• No high-risk features above
• Ongoing indication for anticoagulation exists

The activated charcoal option is particularly relevant for vomiting scenarios: if given within 2 hours of ingestion, it reduces apixaban absorption by 50%; even at 6 hours post-dose, it still reduces absorption by 27% 1. This can be useful if overdose or accidental double-dosing is suspected.